Close

Search

Subscribe
Browse Tag

TCE

2 Articles
Illustration of a trispecific T-cell engager connecting a blue T cell to a purple multiple myeloma cell, with GSK and Chimagen Biosciences logos.

GSK Returns to Chimagen for Multiple Myeloma T-Cell Engager in Deal Worth Up to $750 Million

By Henry Tseng
No Comments on GSK Returns to Chimagen for Multiple Myeloma T-Cell Engager in Deal Worth Up to $750 Million
2 Min Read

GSK is expanding its relationship with China’s Chimagen Biosciences, agreeing to acquire global rights to an experimental trispecific T-cell engager for multiple myeloma in a transaction worth up to $750 million. The agreement, announced September 15,…

Illustration of Simcere Zaiming’s SIM0660 tri-specific antibody engaging CD3 on a T cell and CD19 and CD79a on a B cell to trigger B-cell killing.

Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal

By Chris Chen
No Comments on Simcere Zaiming Out-Licenses SIM0660, a Tri-specific T-cell Engager, to Roche in $1.53 Billion Global Deal
5 Min Read

Simcere Zaiming, the oncology-focused subsidiary of China’s Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for SIM0660, a preclinical tri-specific T-cell engager targeting CD79a, CD19 and CD3. The…